What’s Happening
Chatter
- I graduated this weekend!
- A perspective from the inside
- GSK hiring freeze – uncertainty
- Let’s build it now
- Fare Thee Well
- Advice appreciated: Salary expectation check/burnout management plan
- Which are the worst sponsor you may work with ? Also CROs ?
- Cra promotion salary
- CFR Compliant Signature Questions
- Clinical Research Job Opportunities for someone who lives in the US
- how to get a job offer in Biotech in the current market?
- Do Labcorp do studies on animal testing? I’m so confused with their job descriptions
- Should I Negotiate Salary???
- NIH killed grants on orders from Elon Musk’s DOGE. Court documents and internal correspondence show the cost-cutting force has broad control over the world’s largest public biomedical funder.
- 1.5 Years in… Feeling Imposter Syndrome
Charts
Research
Longboard Pharma and Bexisaserin
Longboard Pharma was acquired by H. Lundbeck A/S on Oct 14, 2024 at about $60 per share. The deal valued Longboard at roughly $2.6 billion dollars, which made it one of the highest returning biopharma stocks of the year. That acquisition price, if closed on, will deliver an 800% return for shareholders YTD at time of writing. Today we will take a closer look at this clinical stage pharma company, and its primary asset, bexicaserin.
…